Newborn screening is a service provided by state public health laboratories that ensures all babies are screened for certain conditions that can cause serious health problems within 24-48 hours after birth. Many babies born with these conditions do not show any signs at birth and appear healthy. By screening all babies, this testing can change a baby’s life by helping health professionals make a diagnosis early and begin treatment before serious problems develop.
In 2010, the Department of Health and Human Services (HHS) announced the addition of severe combined immunodeficiency (SCID) to the recommended uniform screening panel (RUSP). As of 2018, all 50 states in the U.S. screen babies for SCID. Because the blood test used to screen for SCID measures T cells, it also flags infants with related T cell deficiencies, including DiGeorge/22q11.2 deletion syndrome and ataxia-telangiectasia.
Screening tests for other types of PI are still in the research stage. Testing called Kappa rearrangement excision circles (KRECs) estimates the number of immature B cells, which are low in PIs like X-linked agammaglobulinemia (XLA). In the future, it may be possible to sequence a newborn’s entire genome and identify all or most types of PI. However, both technical and ethical challenges of this type of testing must be addressed first.
New conditions are nominated by the public and reviewed by the Advisory Committee on Heritable Disorders in Newborns and Children, which is run by the Health Resources and Services Administration (HRSA). Accepted conditions must have:
Once a condition is added by the committee to the RUSP, states decide on when and how to implement screening for the condition. Ten states have passed RUSP alignment legislation requiring screening for new conditions added to the RUSP to be implemented by the state public health lab within a certain amount of time, typically two years. RUSP alignment legislation ensures that states don’t lag behind on screening for serious conditions and provides funding for the addition of new screening tests to a state’s current panel.
As technology emerges, there will be more newborn screening tests available for types of PI that are not detected with the SCID screening test. Building on previous success with SCID, IDF is prepared to advocate for another nationwide newborn screening campaign for additional PI conditions when such technology is feasible.
When we need policymakers to hear the PI community’s perspective, you will receive an Action Alert by email. Customize each alert with your information and hit send. It's that easy.Sign up today
Read about IDF's role in implementing newborn screening for severe combined immunodeficiency (SCID) across the U.S.
Receive news and helpful resources to your cell phone or inbox. You can change or cancel your subscription at any time.